Abstract
This article presents results from the How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention trial [HEAT PPCI; NCT01519518]. All patients with ST-segment elevation myocardial infarction presenting at a single United Kingdom center were randomized to open-label treatment with heparin (70 units/kg body weight preprocedure) or bivalirudin (bolus of 0.75 mg/kg followed by 1.75 mg/kg/hour infusion during the procedure) on top of preprocedure dual antiplatelet therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
